Summary by Futu AI
EyePoint Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of August 16, 2024, at 4:00 P.M. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that EyePoint Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.